 CAMBRIDGE, Mass., Nov. 02, 2020 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Art Taveras, Ph.D., as Chief Scientific Officer. Dr. Taveras will lead all research and non-clinical development functions supporting the companys pipeline of investigational therapies. 